



SPARC/Sec/SE/2024-25/028

July 26, 2024

To,

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI LODR”), we would like to inform about that Dr. Mudgal Kothekar, Vice President and Dr. Sandeep Inamdar, Vice President – Clinical Development, have been designated as Senior Management Personnel of the Company effective from July 26, 2024.

The details as required under Regulation 30 read with Part A of Schedule III of the SEBI LODR and SEBI Circular No. SEBI/HO/CFD/CFD-PoD1/P/CIR/2023/123 dated July 13, 2023, along with details of the appointment is enclosed herewith as Annexure A.

The Intimation is also available on the website of the Company at www.sparclife.com

You are requested to take the same on record.

Yours faithfully,

For **Sun Pharma Advanced Research Company Limited**

Kajal Damania
Company Secretary and Compliance Officer
ICSI Membership No. A29764

Encl: As above

Annexure A

SR.NO	PARTICULARS	DETAILS
1	Name of Senior Management Personnel	Dr. Mudgal Kotheekar & Dr. Sandeep Inamdar
2	Reason for change	Dr. Mudgal Kotheekar, VP – Clinical Development & Dr. Sandeep Inamdar, VP – Clinical Development have been designated as Senior Management Personnel of the Company effective from July 26, 2024.
3	Date of Appointment	July 26, 2024
4	Brief profile (in case of appointment)	<p>Dr. Mudgal Kotheekar is MD in Pharmacology with an experience of more than 20 years in Clinical Development. He is working at Sun Pharma Advanced Research Company Ltd (SPARC) since Aug 2017. Presently, he is vice president - Clinical Development at SPARC. In the past he has worked in companies like Emcure Pharmaceuticals Ltd, Piramal Life Sciences Limited, Daiichi Sankyo and Panacea Biotec Limited. He was heading the Clinical Development at Biocon Research Limited, Bangalore before he joined SPARC. He has extensive experience in global clinical development of new chemical entities, new biological entities and biosimilars across therapeutic areas including Oncology, Immunology, Dermatology and Diabetes.</p> <p>Dr.Sandeep Inamdar is a licensed physician with over 20 years experience in the biopharmaceutical industry across all phases of clinical development. He has been with Sun Pharma Advanced Research Company Limited (SPARC) since January 2020 and currently heads the Oncology Product Development Group as Vice-President of Clinical Development. Prior to joining SPARC, Sandeep led Early Clinical Development at Five Prime Therapeutics (acquired by Amgen Inc.), a San Francisco Bay Area based biotech company focused on immune-oncology therapies. He has held positions of increasing responsibility across industry leading Fortune 500 pharmaceutical companies such as Amgen and</p>

		<p>GlaxoSmithkline as well as small and mid-sized biotech organizations including Acerta Pharma (acquired by Astra-Zeneca Plc.) and Onyx Pharmaceuticals (acquired by Amgen Inc.) in the United States. Sandeep started his career at Amgen Inc. where he was responsible for executing on large scale clinical programs in supportive care oncology. He also worked on the NDA/EMA submission of Carfilzomib (Kyprolis) in multiple myeloma and on pivotal stage development of Acalabrutinib (Calquence) in Non-Hodgkin's Lymphoma. Sandeep earned his MBBS from Grant Medical College, Mumbai and has an MBA from University of California at Los Angeles (UCLA).</p>
5	<p>Disclosure of Relationship between Directors (in case of appointment)</p>	<p>Not Applicable</p>